BACKGROUND: Individuals initially diagnosed with type 2 diabetes (T2D) might exhibit positivity for diabetes-associated autoantibodies (DAA +). We investigated the prevalence of DAA positivity in a group of individuals with T2D who were referred to a tertiary diabetes centre within a pre-specified period of time. We aimed to identify characteristics linked with DAA positivity by comparing DAA + individuals with their DAA-negative counterparts. METHODS: This was a cross-sectional study into which all T2D patients referred to the National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia, between 1 January and 30 June 2016 were included. Data on > 70 participants' characteristics, including antibodies against glutamic acid decarboxylase (anti-GAD65), insulinoma-associated antigen IA-2 (IA-2A) and insulin (IAA), were collected. RESULTS: Six hundred and ninety-two individuals (387, 55.6% female) with a median (range) age of 62 (24-83) years, HbA1c of 8.9 (5.0-15.7)% [74 (31-148 mmol/mol)] and diabetes duration of 13.0 (0-42) years were analysed. One hundred and forty-five (145/692, 21.0%) tested positive for at least one DAA; 136/692 (19.7%) were positive for anti-GAD65, 21/692 (3.0%) were positive for IA-2A and 9/692 (1.3%) were positive for IAA. Only 84.9% of the DAA + individuals aged > 30 years at the time of diabetes diagnosis met the current diagnostic criteria for latent autoimmune diabetes of adults (LADA). DAA + differed from DAA - individuals in multiple characteristics, including the incidence of hypoglycaemia. CONCLUSION: Several pathological processes linked with distinct types of diabetes can develop in parallel, including insulin resistance and autoimmune insulitis. In this single-centre cross-sectional study from Slovakia, we report a higher than previously published prevalence of DAA positivity in a group of individuals with a formal diagnosis of T2D.

1st Department of Medicine University Hospital Martin Martin Slovakia

Department of Oncology and Metabolism University of Sheffield Sheffield UK

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Jessenius Faculty of Medicine in Martin Comenius University Bratislava Slovakia

National Institute of Endocrinology and Diabetology Ľubochňa Slovakia

Zobrazit více v PubMed

Laugesen E, Ostergaard JA, Leslie RD, Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med. 2015;32(7):843–52. PubMed PMC

Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69(10):2037–2047. doi: 10.2337/dbi20-0017. PubMed DOI PMC

Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36(4):908–913. doi: 10.2337/dc12-0931. PubMed DOI PMC

Maioli M, Pes GM, Delitala G, et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. Eur J Endocrinol. 2010;163(4):541–549. doi: 10.1530/EJE-10-0427. PubMed DOI

Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62(2):543–550. doi: 10.2337/db12-0207. PubMed DOI PMC

Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350(9087):1288–1293. doi: 10.1016/S0140-6736(97)03062-6. PubMed DOI

Tiberti C, Giordano C, Locatelli M, et al. Identification of tyrosine phosphatase 2(256–760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes. 2008;57(5):1276–1283. doi: 10.2337/db07-0874. PubMed DOI

Zinman B, Kahn SE, Haffner SM, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004;53(12):3193–3200. doi: 10.2337/diabetes.53.12.3193. PubMed DOI

Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48(1):150–157. doi: 10.2337/diabetes.48.1.150. PubMed DOI

Zaharieva ET, Velikova TV, Tsakova AD, Kamenov ZA. Prevalence of positive diabetes-associated autoantibodies among type 2 diabetes and related metabolic and inflammatory differences in a sample of the Bulgarian population. J Diabetes Res. 2017;2017:9016148. doi: 10.1155/2017/9016148. PubMed DOI PMC

Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating L. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia. 2008;51(5):846–852. doi: 10.1007/s00125-008-0967-2. PubMed DOI

Rolandsson O, Hampe CS, Wennberg P, et al. Prevalence and regional distribution of autoantibodies against GAD65Ab in a European population without diabetes: the EPIC-interact study. Diabetes Care. 2015;38(8):e114–e115. doi: 10.2337/dc15-0305. PubMed DOI PMC

Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359–362. doi: 10.2337/diab.42.2.359. PubMed DOI

Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206–2212. doi: 10.1007/s00125-005-1960-7. PubMed DOI

Legato MJ. Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy. Am J Cardiol. 2000;86(12A):15L–L18. doi: 10.1016/S0002-9149(00)01463-6. PubMed DOI

Christensen MB, Gaede P, Hommel E, Gotfredsen A, Norgaard K. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. Diabetes Metab. 2020;46(1):61–65. doi: 10.1016/j.diabet.2019.02.002. PubMed DOI

Radtke MA, Midthjell K, Nilsen TI, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care. 2009;32(2):245–250. doi: 10.2337/dc08-1468. PubMed DOI PMC

Rasouli B, Grill V, Midthjell K, Ahlbom A, Andersson T, Carlsson S. Smoking is associated with reduced risk of autoimmune diabetes in adults contrasting with increased risk in overweight men with type 2 diabetes: a 22-year follow-up of the HUNT study. Diabetes Care. 2013;36(3):604–610. doi: 10.2337/dc12-0913. PubMed DOI PMC

Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002;51(6):1754–1762. doi: 10.2337/diabetes.51.6.1754. PubMed DOI

Desai M, Cull CA, Horton VA, et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia. 2007;50(10):2052–2060. doi: 10.1007/s00125-007-0745-6. PubMed DOI

Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care. 2017;40(5):655–662. doi: 10.2337/dc16-2177. PubMed DOI

Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–1747. doi: 10.2337/db13-0468. PubMed DOI